Abstract:The success of immune checkpoint blockade (ICB) promotes the immunotherapy to be a new pillar in cancer treatment. However, the low response rate of the ICB therapy limits its application. To increase the response rate and enhance efficacy, the ICB combination therapy has emerged and its clinical trials are increasing. Nevertheless, the gene expression profile and its pattern of ICB combination were not comprehensively studied, which limits the understanding of the ICB combination therapy and the identification of new drugs. Here, we constructed ICBcomb (http://bioinfo.life.hust.edu.cn/ICBcomb/), a comprehensive database, by analyzing the human and mouse expression data of the ICB combination therapy and comparing them between groups treated with ICB, other drugs or their combinations. ICBcomb contains 1399 samples across 29 cancer types involving 52 drugs. It provides a user-friendly web interface for demonstrating the results of the available comparisons in the ICB combination therapy datasets with five functional modules: [1, 2] the 'Dataset/Disease' modules for browsing the expression, enrichment and comparison results in each dataset or disease; [3] the 'Gene' module for inputting a gene symbol and displaying its expression and comparison results across datasets/diseases; [4] the 'Gene Set' module for GSVA/GSEA enrichment analysis on the built-in gene sets and the user-input gene sets in different comparisons; [5] the 'Immune Cell' module for immune cell infiltration comparison between different groups by immune cell abundance analysis. The ICBcomb database provides the first resource for gene expression profile and comparison in ICB combination therapy, which may provide clues for discovering the mechanism of effective combination strategies and new combinatory drugs.

Supplementary Figure from ICBatlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics from Transcriptome Profiles

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

ICBatlas: A comprehensive resource for depicting immune checkpoint blockade therapy characteristics from transcriptome profiles

Supplementary Figure S9 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer

Supplementary Figure from Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Data from Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy

Supplementary Figure 2 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Supplementary Methods, Tables 1 - 2, Figure Legend from Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions Via Reverse Hepatocellular Carcinoma–Induced Immune Suppression

Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Figure S1 from B7 Blockade Alters the Balance Between Regulatory T Cells and Tumor-reactive T Cells for Immunotherapy of Cancer

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Supplementary Figure Legends from DGKA Mediates Resistance to PD-1 Blockade

Supplementary Figure S9 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure S3 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer

Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8<sup>+</sup> T-cell Effector Functions in Cancer Immunotherapy

ICBcomb: a comprehensive expression database for immune checkpoint blockade combination therapy

Supplementary Table from Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and Sctime Portal